fluorouracil topical / Generic mfg. - LARVOL DELTA

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (clinicaltrials.gov) - P3 | N=408 | Recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Trial completion date: Jun 2034 ➔ Jun 2029

Trial completion date • Colorectal Cancer • Oncology • Solid Tumor

Long-course preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study. (PubMed, Ann Oncol) - P3 | "The superiority of preoperative short-course/CCT over chemoradiation was not demonstrated."

Clinical • Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Rectal Cancer • Solid Tumor

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. (PubMed, N Engl J Med) - P3 | "Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events. (Funded by Merck Sharp and Dohme and by Stand Up to Cancer; KEYNOTE-177 ClinicalTrials.gov number, NCT02563002.)."

Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: City of Hope Medical Center | Initiation date: Jul 2026 ➔ Dec 2026

Trial initiation date • Colorectal Cancer • Oncology • Solid Tumor

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. (PubMed, Lancet Oncol) - "Although the addition of cetuximab to chemotherapy improves the overall survival in some studies in patients with advanced, inoperable metastatic disease, its use in the perioperative setting in patients with operable disease confers a significant disadvantage in terms of overall survival. Cetuximab should not be used in this setting."

Clinical • Journal • P3 data • Cardiovascular • Dermatology • Gastrointestinal Cancer • Gene Therapies • Liver Cancer • Mucositis • Oncology • Pain • Stomatitis

NRG-HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA (clinicaltrials.gov) - P2/3 | N=924 | Active, not recruiting | Sponsor: NRG Oncology | Trial completion date: Dec 2026 ➔ Dec 2031

Biomarker • Trial completion date • Epstein-Barr Virus Infections • Head and Neck Cancer • Infectious Disease • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

4% 5-Fluorouracil Cream for Actinic Keratoses: First Report of Efficacy and Tolerability in a Person Living With Human Immunodeficiency Virus Infection. (PubMed, Clin Case Rep) - "The patient had previously undergone several treatments, including cryotherapy, diclofenac gel, and tirbanibulin, with only temporary improvement. Given the increased oncologic risk in immunocompromised patients, timely and effective treatment of AK is essential. Nevertheless, the limited evidence available in this specific population underscores the need for further prospective studies to better define management strategies and long-term outcomes."

Journal • Actinic Keratosis • Dermatology • Human Immunodeficiency Virus • Infectious Disease • Oncology • Pruritus • Skin Cancer • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

NCI-2022-09458: FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=20 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor • POLE

Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. (PubMed, J Nutr) - P1/2 | "Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer. This trial was registered at clinicaltrials.gov as NCT01490996 and at www.clinicaltrialsregister.eu as EudraCT 2011-002289-19."

Clinical • Journal • P2a data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in the treatment of Bowen's disease: long-term results of a multicenter randomized controlled trial (EADV 2026) - No abstract available

Clinical • Bowens Disease

Characteristics, Management, and Outcomes of Rare Topical 5-Fluorouracil-Induced Cutaneous Eruptions: A Systematic Review (EADV 2026) - No abstract available

Review

A Prebiotic and panthenol-containing repair balm improves tolerability of topical 5-Fluorouracil field therapy for actinic keratoses: a randomised controlled trial (EADV 2026) - No abstract available

Clinical • Actinic Keratosis • Dermatology

Real-time LC-OCT monitoring of scalp hypertrophic actinic keratosis clearance following cryotherapy, laser, and 5-fluorouracil therapy. (PubMed, Front Med (Lausanne)) - "To characterize LC-OCT response patterns in scalp hAKs treated with ablative CO2 laser, cryotherapy, or topical 0.5% 5-fluorouracil/10% salicylic acid, and to evaluate the potential role of LC-OCT in identifying persistent imaging features suggestive of incomplete treatment response requiring retreatment or treatment escalation. Topical 5-FU/SA showed heterogeneous responses; 65% of lesions, mainly KIN 3/PRO III, required escalation to a physical modality. LC-OCT enables non-invasive monitoring of treatment-related hAKs modifications and may identify persistent imaging abnormalities despite apparent clinical resolution, supporting individualized sequential treatment strategies."

Journal • Actinic Keratosis • Dermatology • Oncology

Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. (PubMed, N Engl J Med) - P3 | "Treatment included office-based ablative procedures, ablation or excision under anesthesia, or the administration of topical fluorouracil or imiquimod. Among participants with biopsy-proven anal HSIL, the risk of anal cancer was significantly lower with treatment for anal HSIL than with active monitoring. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT02135419.)."

Clinical • Journal • Anal Carcinoma • Anesthesia • Cervical Cancer • Gastrointestinal Cancer • Human Immunodeficiency Virus • Immunology • Infectious Disease • Oncology • Solid Tumor

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Cholangiocarcinoma • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

NRG-HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA (clinicaltrials.gov) - P2/3 | N=924 | Active, not recruiting | Sponsor: NRG Oncology | N=685 ➔ 924 | Trial completion date: Feb 2032 ➔ Dec 2026

Biomarker • Enrollment change • Trial completion date • Epstein-Barr Virus Infections • Head and Neck Cancer • Infectious Disease • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

CAR-T Cell Therapy-Associated Coagulopathy: From Immunothrombotic Storm Mechanisms to Precision Management Strategies. (PubMed, Crit Rev Oncol Hematol) - "In this review, we synthesize current evidence on CARAC pathobiology, emphasizing its dynamic transition from early procoagulant endothelial conversion to secondary hyperfibrinolysis and consumptive coagulopathy. We delineate disease-specific phenotypes, including hemorrhage-prone B-cell acute lymphoblastic leukemia, thrombotic large B-cell lymphoma and assay-confounded multiple myeloma, and highlight key diagnostic pitfalls such as tocilizumab-associated fibrinogen decline. To support standardization, we propose a phase-adapted conceptual framework integrating laboratory kinetics, clinical events and functional coagulation assessment. Finally, we outline precision management strategies spanning risk-adapted anticoagulation, hemostatic rescue and targeted treatment of delayed inflammatory and endothelial complications."

Journal • Review • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery (clinicaltrials.gov) - P3 | N=537 | Active, not recruiting | Sponsor: Children's Oncology Group | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Hepatoblastoma • Hepatocellular Cancer • Liver Cancer • Oncology • Pediatrics • Solid Tumor • AFP • SMARCB1

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - P3 | N=2431 | Completed | Sponsor: National Cancer Institute (NCI) | Trial completion date: Apr 2027 ➔ May 2026 | Active, not recruiting ➔ Completed

Biomarker • Trial completion • Trial completion date • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • MSH2 • MSI

LAP100: Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - P3 | N=356 | Recruiting | Sponsor: NRG Oncology | Trial completion date: Oct 2035 ➔ Oct 2030

Trial completion date • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Extramammary Paget's Disease Mimicking Squamous Cell Carcinoma In Situ: The Diagnostic Challenge of Recalcitrant Anogenital Lesions. (PubMed, Cureus) - "The patient had a previous histopathological diagnosis of squamous cell carcinoma in situ and was treated with topical 5% 5-fluorouracil for six months...Taking new biopsies for recalcitrant lesions is critical. An appropriately selected, broad immunohistochemical panel is a fundamental tool to differentiate intraepidermal malignancies in complex anogenital cases."

Journal • Bowens Disease • Dermatology • Dermatopathology • Oncology • Rare Diseases • Squamous Cell Carcinoma

NRG-GI006: Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer (clinicaltrials.gov) - P3 | N=300 | Active, not recruiting | Sponsor: NRG Oncology | Recruiting ➔ Active, not recruiting

Enrollment closed • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • Thoracic Cancer

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov) - P3 | N=129 | Not yet recruiting | Sponsor: City of Hope Medical Center | Initiation date: Jul 2026 ➔ Oct 2026

Trial initiation date • Appendix Cancer • Colorectal Cancer • Oncology • Solid Tumor • BRAF

LAP100: Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - P3 | N=356 | Recruiting | Sponsor: NRG Oncology | Trial completion date: Oct 2030 ➔ Oct 2035

Trial completion date • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: M.D. Anderson Cancer Center | Active, not recruiting ➔ Completed | Trial completion date: Jul 2027 ➔ Aug 2026 | Trial primary completion date: Jul 2027 ➔ Aug 2026

Trial completion • Trial completion date • Trial primary completion date • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • PD-L1